Rheumatoid Arthritis Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Rheumatoid Arthritis stocks.

Rheumatoid Arthritis Stocks Recent News

Date Stock Title
Jul 3 EBS Emergent scores US medical countermeasure contracts worth over $250m
Jul 3 REGN Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
Jul 3 REGN Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
Jul 3 REGN Sanofi, Regeneron win EU label expansion for Dupixent in COPD
Jul 3 EBS Why Is Vaccine Maker Emergent BioSolutions Stock Trading Higher On Tuesday? (UPDATED)
Jul 3 REGN Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
Jul 2 REGN Insider Sale: Director Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN)
Jul 2 EBS Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
Jul 2 EBS Emergent BioSolutions secures $250M contracts for the U.S. government
Jul 2 EBS Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
Jul 2 REGN Insiders At Regeneron Pharmaceuticals Sold US$26m In Stock, Alluding To Potential Weakness
Jul 1 REGN Regeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug
Jul 1 CANF Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson
Jul 1 MESO Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week
Jun 28 ARGX Argenx: Strong Setup For Outperformance In 2025
Jun 28 REGN What's Going On With Regeneron Pharmaceuticals Stock On Friday?
Jun 28 REGN Regeneron lymphoma antibody drug endorsed for conditional approval in EU
Jun 28 REGN Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Jun 28 CANF Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix
Jun 27 REGN Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects joints. It typically results in warm, swollen, and painful joints. Pain and stiffness often worsen following rest. Most commonly, the wrist and hands are involved, with the same joints typically involved on both sides of the body. The disease may also affect other parts of the body. This may result in a low red blood cell count, inflammation around the lungs, and inflammation around the heart. Fever and low energy may also be present. Often, symptoms come on gradually over weeks to months.While the cause of rheumatoid arthritis is not clear, it is believed to involve a combination of genetic and environmental factors. The underlying mechanism involves the body's immune system attacking the joints. This results in inflammation and thickening of the joint capsule. It also affects the underlying bone and cartilage. The diagnosis is made mostly on the basis of a person's signs and symptoms. X-rays and laboratory testing may support a diagnosis or exclude other diseases with similar symptoms. Other diseases that may present similarly include systemic lupus erythematosus, psoriatic arthritis, and fibromyalgia among others.The goals of treatment are to reduce pain, decrease inflammation, and improve a person's overall functioning. This may be helped by balancing rest and exercise, the use of splints and braces, or the use of assistive devices. Pain medications, steroids, and NSAIDs are frequently used to help with symptoms. Disease-modifying antirheumatic drugs (DMARDs), such as hydroxychloroquine and methotrexate, may be used to try to slow the progression of disease. Biological DMARDs may be used when disease does not respond to other treatments. However, they may have a greater rate of adverse effects. Surgery to repair, replace, or fuse joints may help in certain situations. Most alternative medicine treatments are not supported by evidence.RA affects about 24.5 million people as of 2015. This is between 0.5 and 1% of adults in the developed world with 5 and 50 per 100,000 people newly developing the condition each year. Onset is most frequent during middle age and women are affected 2.5 times as frequently as men. In 2013, it resulted in 38,000 deaths up from 28,000 deaths in 1990. The first recognized description of RA was made in 1800 by Dr. Augustin Jacob Landré-Beauvais (1772–1840) of Paris. The term rheumatoid arthritis is based on the Greek for watery and inflamed joints.

Browse All Tags